You are here

Ipsen

Pfizer's fortunes overshadow first-quarter dealmaking

Pfizer's fortunes overshadow first-quarter dealmaking

EP Vantage

Flag link:

FDA agrees to give Ipsen's rare disease drug another look as palovarotene saga rumbles on

FDA agrees to give Ipsen's rare disease drug another look as palovarotene saga rumbles on

Fierce Biotech

fibrodysplasia ossificans progressiva

Flag link:

Ipsen reports positive data from pancreatic ductal adenocarcinoma trial

Ipsen reports positive data from pancreatic ductal adenocarcinoma trial

Clinical Trials Arena

metastatic pancreatic cancer

pancreatic cancer

clinical trials

Flag link:

Irlab's shares plummet 60% after Ipsen-partnered Parkinson's drug flunks phase 2 trial

Irlab's shares plummet 60% after Ipsen-partnered Parkinson's drug flunks phase 2 trial

Fierce Biotech

clinical trials

Parkinson's Disease

Flag link:

Biopharma’s bolt-on bonanza is set to continue

Biopharma’s bolt-on bonanza is set to continue

EP Vantage

Bristol Myers Squibb

Flag link:

Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting

Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting

BioPharma Dive

Chiesi Farmaceutici

Flag link:

Ipsen's rare disease candidate rejected after mounting setbacks, delays

Ipsen's rare disease candidate rejected after mounting setbacks, delays

Fierce Biotech

Flag link:

AbbVie, Ipsen exit R&D deals to cap off lousy year for Exicure

AbbVie, Ipsen exit R&D deals to cap off lousy year for Exicure

Fierce Biotech

Flag link:

Go or no go? Mirati heads to the FDA

Go or no go? Mirati heads to the FDA

EP Vantage

Mirati Therapeutics

Gilead Sciences

Coherus Biosciences

TG Therapeutics

Flag link:

Halloween adcomm postponed as FDA seeks more Ipsen data on ultra rare disorder drug candidate

Halloween adcomm postponed as FDA seeks more Ipsen data on ultra rare disorder drug candidate

Endpoints

fibrodysplasia ossificans progressiva

Flag link:

Go or no go? GSK takes its turn with a novel anemia class

Go or no go? GSK takes its turn with a novel anemia class

EP Vantage

Amicus Therapeutics

Y-mAbs Therapeutics

Flag link:

Ipsen becomes the latest pharma to expand in Ireland, with a $50M investment in its facility in Dublin suburbs

Ipsen becomes the latest pharma to expand in Ireland, with a $50M investment in its facility in Dublin suburbs

Endpoints

drug manufacturing

Flag link:

ESMO: It’s early days for Pfizer’s EZH2 inhibitor, but there’s a glimpse of hope for some

ESMO: It’s early days for Pfizer’s EZH2 inhibitor, but there’s a glimpse of hope for some

Fierce Biotech

EZH2 inhibitors

Flag link:

Trick, or treat? FDA plans Halloween adcomm for Ipsen’s second chance at rare disease drug

Trick, or treat? FDA plans Halloween adcomm for Ipsen’s second chance at rare disease drug

Endpoints

Flag link:

PhIII fail in overall survival measure clouds Ipsen's expansion plans for cancer drug Onivyde

PhIII fail in overall survival measure clouds Ipsen's expansion plans for cancer drug Onivyde

Endpoints

small cell lung cancer

clinical trials

Flag link:

Ipsen jumps into the TCR space, teaming with startup helmed by former Merck KGaA cancer chief

Ipsen jumps into the TCR space, teaming with startup helmed by former Merck KGaA cancer chief

Endpoints

Marengo Therapeutics

TCR immunotherapy

Flag link:

Epizyme SEC filing details its desperate days in free fall before $247M sale to Ipsen

Epizyme SEC filing details its desperate days in free fall before $247M sale to Ipsen

Fierce Pharma

Flag link:

Ipsen beefs up in oncology, buying US biopharma Epizyme

Ipsen beefs up in oncology, buying US biopharma Epizyme

Pharmaforum

Flag link:

First-quarter biotech risers work hard for the win

First-quarter biotech risers work hard for the win

EP Vantage

Lantheus Medical

Flag link:

Pages